Please try another search
For the three months ended 31 March 2022, Yungjin Pharm Co Ltd revenues increased 20% to W52.33B. Net loss decreased 18% to W1.45B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Commission Paid decrease of 9% to W2.38B (expense), Miscellaneous Non-Operating Income increase from W43.5M to W108.4M (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 52331.61 | 53922.34 | 49458.37 | 49041.01 |
Gross Profit | 16057.49 | 16029.37 | 13805.75 | 13733.11 |
Operating Income | -790.82 | -2837.57 | -4159.48 | -4919.62 |
Net Income | -1453.29 | -1707.97 | -3810.14 | -4290.37 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 194095.21 | 185040.17 | 190181.8 | |
Total Liabilities | 89209.75 | 80478.77 | 81810.03 | |
Total Equity | 104885.46 | 104561.4 | 108371.77 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 8367.76 | 10326.34 | 1791.34 | |
Cash From Investing Activities | -11637.61 | -6986.64 | -3830.31 | |
Cash From Financing Activities | 3306.73 | -2286.34 | 2145.07 | |
Net Change in Cash | 36.88 | 1053.36 | 106.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review